Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.61 |
| ▸ | PPARA | Q07869 | 14/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | PPARD | Q03181 | 5/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Reglitazar SCHEMBL14544595 | 1.00 | PPARG (0.61) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL14281405 | 0.91 | FFAR1 (0.61) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL5918535 | 0.84 | PPARG (0.44) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL5918538 | 0.84 | PPARG (0.52) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL7909696 | 0.84 | PPARG (0.60) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL6052101 | 0.81 | PPARG (0.61) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL3279259 | 0.81 | PPARG (0.72) | PPARGPPARAPPARD | |
| SCHEMBL7909689 | 0.81 | PPARG (0.63) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL4283015 | 0.81 | PPARG (0.63) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL170065 | 0.81 | PPARG (0.63) | PPARGPPARACYP3A4CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1023 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | claimed |
| CN-118922890-A | Measurement, diagnosis, treatment and management of metabolic syndrome | 费尔南多·加西亚·萨达 | 2024-11-08 | — | — | CN | claimed |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | KADDURAH DAOUK RIMA F (US) | 2023-11-23 | — | — | US | claimed |
| WO-2023161832-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | GARCIA SADA FERNANDO (MX) | 2023-08-31 | — | — | WO | claimed |
| US-20230266340-A1 | Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome | SILTI AG (CH) | 2023-08-24 | — | — | US | claimed |
| WO-2022081350-A2 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | DUKE UNIVERSITY (US) | 2022-04-21 | — | — | WO | claimed |
| US-8338480-B2 | Combination treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | claimed |
| WO-2012158123-A1 | COMPOUNDS AND METHODS FOR TREATING INSULIN RESISTANCE SYNDROME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-11-22 | — | — | WO | claimed |
| US-20100292277-A1 | COMBINATION TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-11-18 | — | — | US | claimed |
| EP-2001461-A2 | COMBINATION TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2008-12-17 | — | — | EP | claimed |
| US-6329403-B1 | INSULIN SENSITIZER SELECTED FROM PIOGLITAZONE, TROGLITAZONE, ROSIGLITAZONE, 4-(4-(2-(5-METHYL-2-PHENYLOXAZOL-4-YL)ETHOXY) BENZYL)ISOXAZOLIDIN-3,5-DIONE OR SALT, IN COMBINATION WITH SIBUTRAMINE OR MAZINDOL | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-11 | — | — | US | claimed |
| WO-2000041690-A9 | USE OF THIAZOLIDINEDIONES TO AMELIORATE THE ADVERSE CONSEQUENCES OF MYOCARDIAL ISCHEMIA ON MYOCARDIAL FUNCTION AND METABOLISM | UNIV CALIFORNIA (US) | 2001-10-11 | — | — | WO | claimed |
| US-6150371-A | WITH THE EXCEPTION OF TYPE I DIABETES; INHIBITS INVASION OF ORGAN TISSUE BY CYTOTOXIC LYMPHOCYTES; ADMINISTERING TO A MAMMAL AN ANTIAUTOIMMUNE DISEASE AGENT BEING AN INSULIN RESISTANCE REDUCING AGENT, ANTIDIABETIC, E.G., TROGLITAZONE | SANKYO COMPANY, LIMITED (JP) | 2000-11-21 | — | — | US | claimed |
| WO-2000061127-A2 | USE OF INSULIN SENSITISERS FOR IMPROVING KETOSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-19 | — | — | WO | claimed |
| WO-2000041690-A1 | USE OF THIAZOLIDINEDIONES TO AMELIORATE THE ADVERSE CONSEQUENCES OF MYOCARDIAL ISCHEMIA ON MYOCARDIAL FUNCTION AND METABOLISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-07-20 | — | — | WO | claimed |
| EP-0537802-B1 | N-acylpyrrolidines, process for their preparation and their use for prevention and/or treatment of amnesia | ONO PHARMACEUTICAL CO (JP) | 1999-08-25 | — | — | EP | claimed |
| EP-0919232-A1 | Composition for use in the treatment and prevention of hyperuricemia | Sankyo Company Limited (JP) | 1999-06-02 | — | — | EP | claimed |
| EP-0684242-B1 | ISOXAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | JAPAN TOBACCO INC (JP) | 1999-05-06 | — | — | EP | claimed |
| EP-0796618-A1 | Treatment and prophylaxis of pancreatitis | SANKYO COMPANY LIMITED (JP) | 1997-09-24 | — | — | EP | claimed |
| EP-0684242-A1 | ISOXAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | JAPAN TOBACCO INC. (JP) | 1995-11-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292277-A1 | COMBINATION TREATMENT OF METABOLIC DISORDERS | NR1H3, GPR119, NR1H2 | PPARG 12/4885PPARA 13/4885CYP3A4 1847/4885 |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | SLC25A20, CPT2, NDUFAB1 | PPARG 567/4885PPARA 787/4885CYP3A4 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.